Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 9/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370951 | 0.76 | IMPDH2 (0.66) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL4814398 | 0.76 | AAK1 (0.51) | IMPDH2IMPDH1ALDH1A1AAK1 | |
| SCHEMBL25033577 | 0.76 | GAA (0.53) | IMPDH2IMPDH1CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL11004268 | 0.75 | ALDH1A1 (0.61) | CYP3A4CYP2D6CYP1A2CYP2C9CYP11B1 | |
| SCHEMBL30206740 | 0.75 | ALDH1A1 (0.61) | CYP3A4CYP2D6CYP1A2CYP2C9CYP11B1 | |
| SCHEMBL30206743 | 0.75 | ALDH1A1 (0.61) | CYP3A4CYP2D6CYP1A2CYP2C9CYP11B1 | |
| SCHEMBL4895178 | 0.74 | ALDH1A1 (0.51) | CYP3A4CYP2D6CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12125145 | 0.74 | IMPDH2 (0.55) | IMPDH2IMPDH1CYP3A4CYP2D6AAK1 | |
| Hydrochloric Acid SCHEMBL30206678 | 0.73 | ALDH1A1 (0.65) | CYP3A4CYP2D6CYP1A2CYP2C9CYP11B1 | |
| SCHEMBL472471 | 0.73 | LMNA (0.63) | IMPDH2IMPDH1CYP3A4CYP2D6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | IMPDH2 1292/4885IMPDH1 323/4885CYP3A4 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.